Global Recognition Covance Drug Development has been consistently recognized as a top Global Contract Research Organization (CRO), showcasing a strong reputation and expertise in the industry. Leveraging this accolade can open doors for partnerships and collaborations with pharmaceutical and biotech companies looking for a trusted drug development service provider.

Key Personnel Promotion The promotion of Maryland Franklin to vice president and head of Covance's cell and gene therapy unit highlights the company's investment in cutting-edge areas of drug development. Engaging with Franklin and her team could present an opportunity to explore novel therapeutic avenues and tailor solutions for clients seeking innovative approaches.

Strategic Acquisition LabCorp's acquisition of Covance Drug Development for $6.1B positioned the company as a global player in the industry. Leveraging the expanded international operations and comprehensive drug development services post-acquisition can be a selling point to potential clients looking for a partner with a broad reach and established presence.

Recent Investments Covance's recent investment in renovating preclinical oncology facilities in Ann Arbor indicates a commitment to enhancing infrastructure and capabilities. Highlighting these upgraded facilities can attract clients seeking state-of-the-art research environments and specialized services in oncology drug development.

Rare Industry Achievement Being recognized as winners in the Markie category in both 2017 and 2020 positions Covance as a consistent leader in nonclinical safety assessment. Emphasizing this rare achievement can differentiate the company from competitors and showcase a track record of excellence, appealing to clients prioritizing reliability and expertise.